Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Abstract

The present study investigated the bacterial and fungal communities and cross-domain network interactions in patients with chronic Otitis media in response to the natural monoterpene medicinal 1,8-Cineol as a promising treatment option. While the bacterial community showed modest changes with preserved core genera, the fungal community underwent dramatic diversification and network expansion. This suggests that treatment may have disrupted competitive exclusion mechanisms in the latter, allowing for increased diversity and interactions, despite no significant changes in traditional diversity metrics. Investigations on the microbial community compositions in Otitis media patients upon 1,8-Cineol treatment revealed significantly different initial microbial signatures in responders and non-responders. Notably, therapy-responding COM patients demonstrated a baseline situation with significantly higher abundances of different gram-negative Pseudomonas species. In contrast, significantly elevated levels of various gram-positive Corynebacterium species were observed in the non-responder group compared to the 1,8-Cineol responding patients. These keystone taxa may represent new targets for therapeutic intervention or biomarkers for treatment response.

OriginalspracheEnglisch
Aufsatznummer135
Zeitschriftnpj Systems Biology and Applications
Jahrgang12
Ausgabenummer1
DOIs
PublikationsstatusVeröffentlicht - 11.08.2026

Fördermittel

Open Access funding enabled and organized by Projekt DEAL. We are grateful to all members of the ENT department, University Hospital Schleswig-Holstein, Luebeck, for supporting sample collection, as well as the staff of the Department of Infectious Diseases and Microbiology for microbiological diagnostics of the ear. A.K. and H.B. acknowledge computational support from the OMICS Compute Cluster at the University of Luebeck and support by the Federal Ministry of Research, Technology, and Space project OUTLIVECRC (FKZ 01KD2103A). A.L., R.P., and K.L.B. received funding through the Cassella-med GmbH & Co. KG, Cologne, Germany, Project FDE00400/01.

TrägerTrägernummer
Projekt DEAL
Bundesministerium für Forschung, Technologie und RaumfahrtOUTLIVECRC (FKZ 01KD2103A)
Cassella-med GmbH & Co. KG, Cologne, GermanyProject FDE00400/01

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen
    2. SDG 6 – Sauberes Wasser und sanitäre Einrichtungen
      SDG 6 – Sauberes Wasser und sanitäre Einrichtungen
    3. SDG 9 – Industrie, Innovation und Infrastruktur
      SDG 9 – Industrie, Innovation und Infrastruktur

    Strategische Forschungsbereiche und Zentren

    • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Bacterial and fungal communities and network dynamics in Otitis media patients upon 1,8-Cineol treatment“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Dieses zitieren